Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower
NICE has set a new target for cholesterol levels in people who have had a heart attack or stroke to reduce the risk of them having another, encouraging the use of addition
